Airsupra (budesonide/salbutamol) / AstraZeneca, Avillion - LARVOL DELTA

QUARTZ: Comparative Effectiveness of Switching From Albuterol to Albuterol/Budesonide Versus Adding Low-dose ICS or LTRA to Albuterol (clinicaltrials.gov) - P=N/A | N=8000 | Recruiting | Sponsor: AstraZeneca | N=2669 ➔ 8000 | Not yet recruiting ➔ Recruiting

Enrollment change • Enrollment open • HEOR • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

A Randomized, Placebo-controlled, Double-blind, Multicenter, 12-Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma (ChiCTR) - P3 | N=398 | Completed | Sponsor: Shanghai General Hospital; Shanghai General Hospital

New P3 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

PATIENTS WITH MILD ASTHMA AND HIGHER MANNITOL SENSITIVITY SHOW ENHANCED LUNG FUNCTION RECOVERY POSTCHALLENGE IF TREATED WITH REPETITIVE ALBUTEROL-BUDESONIDE VS ALBUTEROL (CHEST 2026) - No abstract available

Clinical • Asthma • Immunology • Respiratory Diseases

Fasenra: An Asthma Study (clinicaltrials.gov) - P4 | N=40 | Enrolling by invitation | Sponsor: Endeavor Health | Not yet recruiting ➔ Enrolling by invitation

Enrollment open • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma (clinicaltrials.gov) - P3 | N=424 | Completed | Sponsor: AstraZeneca | Active, not recruiting ➔ Completed

Trial completion • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Budget impact analysis for albuterol-budesonide fixed-dose combination in the as needed treatment of adult patients with asthma in Kuwait. (PubMed, J Med Econ) - "This evaluation is relevant to healthcare decision makers for guiding that alb/bud-FDC is budget-saving for eligible patients, while reducing the burden to patients and improving their control and symptoms. These savings should be interpreted within the context of the overall asthma management budget."

HEOR • Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

QUARTZ: Comparative Effectiveness of Switching From Albuterol to Albuterol/Budesonide Versus Adding Low-dose ICS or LTRA to Albuterol (clinicaltrials.gov) - P=N/A | N=2669 | Not yet recruiting | Sponsor: AstraZeneca

HEOR • New trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Efficacy and safety of as-needed albuterol-budesonide versus albuterol alone in mild-to-moderate asthma: a systematic review and meta-analysis (ERS 2026) - "Albuterol-budesonide reduced annualized systemic corticosteroid exposure (mean difference -42.22 mg prednisone-equivalent/year; 95% CI -70.43 to -14.01; p=0.003) and asthma events (risk ratio [RR] 0.59; 95% CI 0.43-0.81; p=0.001). As-needed albuterol-budesonide reduces systemic corticosteroid exposure and improves exacerbation-free survival compared with albuterol alone, without an increase in overall adverse events."

Retrospective data • Review • Asthma • Immunology • Infectious Disease • Inflammation • Respiratory Diseases

Chronic Cough With Reduced Diffusing Capacity and Preserved-Ratio Impaired Spirometry in a Young Never-Smoker With Systemic Lupus Erythematosus: A Diagnostic Pitfall. (PubMed, Cureus) - "She was initially treated for gastroesophageal reflux disease with pantoprazole, without meaningful relief...Her cough improved substantially after inhaled therapy with albuterol and budesonide/glycopyrrolate/formoterol fumarate...This case highlights a diagnostic pitfall: inhaler-responsive chronic cough and a pulmonary function report suggesting obstruction should be evaluated together with post-bronchodilator spirometry, diffusing capacity, imaging, and exposure history. In systemic lupus erythematosus, a persistent cough may be associated with clinically relevant pulmonary function abnormalities even when chest imaging is unrevealing."

Journal • Bronchiectasis • Chronic Cough • Cough • Gastroenterology • Gastroesophageal Reflux Disease • Glomerulonephritis • Immunology • Infectious Disease • Inflammatory Arthritis • Interstitial Lung Disease • Lupus • Lupus Nephritis • Nephrology • Pulmonary Disease • Respiratory Diseases • Systemic Lupus Erythematosus • Tuberculosis

BAIYUN: A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma (clinicaltrials.gov) - P3 | N=1000 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Oct 2026 ➔ Oct 2027 | Trial primary completion date: Oct 2026 ➔ Oct 2027

Trial completion date • Trial primary completion date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

AIRLYMPUS: Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma (clinicaltrials.gov) - P2 | N=556 | Active, not recruiting | Sponsor: Sanofi | Recruiting ➔ Active, not recruiting | N=1147 ➔ 556

Enrollment change • Enrollment closed • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Fasenra: An Asthma Study (clinicaltrials.gov) - P4 | N=40 | Not yet recruiting | Sponsor: Endeavor Health

New P4 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Ventilation and Perfusion in Asthmatics (clinicaltrials.gov) - P4 | N=40 | Recruiting | Sponsor: University of Miami | Not yet recruiting ➔ Recruiting

Enrollment open • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

AIRLYMPUS: Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma (clinicaltrials.gov) - P2 | N=1147 | Recruiting | Sponsor: Sanofi | N=673 ➔ 1147

Enrollment change • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Identification of priority medications for characterizing developmental changes in drug disposition after extremely preterm birth (PAS 2026) - "Eight medications prescribed to manage preterm lung disease (caffeine, furosemide, albuterol, ipratropium, budesonide, levalbuterol, chlorothiazide, and sildenafil) and 7 medications prescribed to provide sedation and/or analgesia (lorazepam, methadone, acetaminophen, dexmedetomidine, clonidine, midazolam, and morphine) were among the top 20 priorities.Conclusion(s): Our findings facilitate the identification of high-priority targets for preterm developmental pharmacology research, highlighting medications for preterm lung disease and sedative/analgesics as particular priorities in this vulnerable population.Table 1: Cohort CharacteristicsFigure 1: Medication utilization rates, PMA spread at prescription and PMA-based priority score in extremely preterm infants hospitalized in US children's hospitals. We identified 15,722 EP infants (Table 1). 48 medications were prescribed in > 1% of study period days. The top 20 medications for utilization, spread, and priority..."

Prematurity • Pulmonary Disease • Respiratory Diseases

ANCHOR: Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care (clinicaltrials.gov) - P4 | N=1511 | Active, not recruiting | Sponsor: AstraZeneca | Trial completion date: Apr 2026 ➔ Mar 2027 | Trial primary completion date: Apr 2026 ➔ Mar 2027

HEOR • Trial completion date • Trial primary completion date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

As-Needed Budesonide Plus Albuterol Is Superior to Albuterol Alone for Poorly Controlled Mild Asthma. (PubMed, Am Fam Physician) - No abstract available

Journal • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Impact of As-needed Albuterol-budesonide on Symptoms in Moderate-to-severe Asthma: A Mandala Post-Hoc Analysis (ATS 2026) - No abstract available

Retrospective data • Asthma • Immunology • Respiratory Diseases

Efficacy and safety of as-needed albuterol-budesonide versus albuterol in patients with asthma aged 12 to <18 years: design of the randomised, double-blind, parallel-group phase IIIb ACADIA trial. (PubMed, BMJ Open Respir Res) - P3 | "Results will be presented at respiratory congresses and published in peer-reviewed journals. NCT06307665."

Journal • P3 data • Asthma • Immunology • Pediatrics • Pulmonary Disease • Respiratory Diseases

Efficacy Of As-needed Albuterol‒Budesonide Versus Albuterol In Participants With Mild Asthma Not On Maintenance Therapy: BATURA Post-hoc Analysis (AAAAI 2026) - "AIRQ score improvement from baseline to week 16 (first measurement time) was greater with albuterol–budesonide versus albuterol (least-squares mean difference −0.32 [95% CI −0.51, −0.13]; p<0.001). Conclusions For patients with uncontrolled mild asthma on SABA-only therapy, as-needed albuterol–budesonide demonstrates early exacerbation risk reduction, with a relatively low NNT, and improved disease control versus albuterol."

Clinical • Retrospective data • Asthma • Immunology • Respiratory Diseases

PaNaMa 12782: Inhaled corticosteroids in young children with episodic wheezing: a multicenter cluster RCT (clinicaltrialsregister.eu) - P4 | N=285 | Not yet recruiting | Sponsor: Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

New P4 trial

Albuterol-Budesonide Treatment in Acute Airway Obstruction Provides Enhanced Lung Function Improvement for Patients With Well-Controlled and Uncontrolled Mild Asthma (AAAAI 2026) - P3 | "FEV1 improvement (LSM[SE] difference) post-mannitol challenge at 480 minutes was greater with as-needed albuterol-budesonide versus albuterol for all participants by 91.19[27.37]; 95%CI [36.69–145.68] mL, p=0.001; well-controlled by 99.06[41.28]; 95%CI [15.85–182.26] mL, p=0.021; and uncontrolled by 80.31[33.81]; 95%CI [11.16-149.45] mL, p=0.024. Conclusions Albuterol-budesonide relieves mannitol-induced acute obstruction better than albuterol over time in controlled and uncontrolled mild asthma."

Clinical • Asthma • Immunology • Respiratory Diseases

Use of as-needed Albuterol–budesonide Is Associated with a Higher Probability of Symptom-free Nights Than as-needed Albuterol in Moderate-to-Severe Asthma (AAAAI 2026) - "Conclusions As-needed albuterol–budesonide results in greater probability of a symptom-free night versus albuterol. This benefit occurs even among patients not experiencing exacerbations."

Asthma • Immunology • Inflammation • Respiratory Diseases

Efficacy of Albuterol-budesonide vs Albuterol in Mild Asthma on Disease Control Over Time (AAAAI 2026) - "At 28 weeks, odds of reaching AIRQ MID were greater in the albuterol–budesonide group (80.8% vs 74.1%, OR=1.55[1.22, 1.97], p<0.001). Conclusions These BATURA findings demonstrate as-needed albuterol–budesonide vs albuterol results in clinically important improvements in disease control in mild asthma."

Clinical • Asthma • Immunology • Respiratory Diseases

Albuterol-budesonide Treatment for Acute Airway Obstruction Provides Enhanced Lung Function Improvement Compared to Albuterol in Mild Asthma Irrespective of Baseline Forced Expiratory Volume in One-second (FEV1) (ATS 2026) - No abstract available

Asthma • Immunology • Respiratory Diseases